EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

The cost-effectiveness of medical versus surgical androgen deprivation therapy for advanced prostate cancer in Tanzania: a Markov model-based analysis

Obadia Nyongole, Malale Tungu, Alphoncina Kagaigai, Amani Anaeli, Amisa Tindamanyile, Prosper Njau, Mucho Mizinduko, David Urassa, Bruno Sunguya, Gasto Frumence

Frontiers in Public Health · 18.09.2026 · 14

DOI: 10.3389/fpubh.2026.1907445 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Frontiers in Public Health, online erschienen am 18.09.2026. Verfasst von Obadia Nyongole und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Androgen Antagonists. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Androgen deprivation therapy (ADT) is a recommended treatment for patients with advanced prostate cancer, mostly for palliative purposes. In limited resource settings, decision-making about palliative treatment should be guided by the overall survival benefit of one option over another, patient life expectancy, quality of life, and cost.

Purpose

This study aimed to evaluate the cost-effectiveness of medical androgen deprivation therapy compared to surgical androgen deprivation therapy among patients with advanced prostate cancer in Tanzania.

Methods

A model-based economic evaluation study design, was conducted using retrospective patient records from tertiary hospitals in Tanzania and published literature. A Markov model with a five-year time horizon was developed to simulate disease progression among patients receiving either medical ADT or surgical ADT. Health states included local recurrence, asymptomatic metastatic disease, symptomatic metastatic disease, death from prostate cancer, and death from other causes. Costs were estimated from provider and societal perspectives and expressed in US$. Health outcomes were measured in quality-adjusted life years (QALYs). Incremental cost-effectiveness ratios (ICERs) were calculated and compared against a willingness-to-pay threshold based on Tanzania’s gross domestic product (GDP) per capita (US$1,099) as the cost-effectiveness threshold. Alternative willingness-to-pay thresholds, including three times GDP per capita (US$3,580), were explored in sensitivity analyses. Probabilistic sensitivity analysis using Monte Carlo simulation was performed to assess uncertainty.

Results

Medical ADT generated higher costs and greater health benefits than surgical ADT. The total cost of medical ADT was estimated at US$50,639.98 compared with US$6,917.51 for surgical ADT. Medical ADT produced a cumulative cohort-level effectiveness equivalent to 105.63 QALYs compared with 4.06 QALYs for surgical ADT, resulting in an incremental gain of 101.58 QALYs. The ICER for medical ADT was US$430.44 per QALY gained, which remained substantially below the selected willingness-to-pay threshold of US$1,099 and alternative threshold of US$3,580 per QALY. Probabilistic sensitivity analyses demonstrated that medical ADT remained cost-effective across a wide range of parameter assumptions.

Conclusion

Medical ADT was more costly but also more effective than surgical ADT for managing advanced prostate cancer in Tanzania. The estimated ICER remained below the willingness-to-pay threshold, indicating that medical ADT represents a cost-effective treatment strategy. Further studies incorporating local utility estimates and long-term survival outcomes are warranted to strengthen economic evidence for prostate cancer management in Tanzania.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAndrogen AntagonistsMaleTanzaniaHumansCost-Benefit AnalysisCost-Effectiveness AnalysisMarkov ChainsRetrospective StudiesQuality-Adjusted Life YearsAgedMiddle Aged

Stichwörter der Autor:innen

advanced prostate cancercost-effectivenessmedical ADTquality-adjusted life years (QALYs)surgical ADT

Substanzen

Androgen Antagonists

Autor:innen und Institutionen

  • Department of Surgery, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
  • Department of Development Studies, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
  • School of Pharmacy, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
  • Ministry of Health, Dodoma, Tanzania.
  • Department of Epidemiology and Biostatistics, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
  • Department of Community Health, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.

Zitieren

APA

Nyongole, O., Tungu, M., Kagaigai, A., Anaeli, A., Tindamanyile, A., Njau, P., Mizinduko, M., Urassa, D., Sunguya, B., & Frumence, G. (2026). The cost-effectiveness of medical versus surgical androgen deprivation therapy for advanced prostate cancer in Tanzania: a Markov model-based analysis. Frontiers in Public Health, 14. https://doi.org/10.3389/fpubh.2026.1907445

Vancouver

Nyongole O, Tungu M, Kagaigai A, Anaeli A, Tindamanyile A, Njau P, et al. The cost-effectiveness of medical versus surgical androgen deprivation therapy for advanced prostate cancer in Tanzania: a Markov model-based analysis. Frontiers in Public Health. 2026;14. doi:10.3389/fpubh.2026.1907445

BibTeX
@article{Nyongole2026,
  author = {Nyongole, Obadia and Tungu, Malale and Kagaigai, Alphoncina and Anaeli, Amani and Tindamanyile, Amisa and Njau, Prosper and Mizinduko, Mucho and Urassa, David and Sunguya, Bruno and Frumence, Gasto},
  title = {The cost-effectiveness of medical versus surgical androgen deprivation therapy for advanced prostate cancer in Tanzania: a Markov model-based analysis},
  journal = {Frontiers in Public Health},
  year = {2026},
  volume = {14},
  doi = {10.3389/fpubh.2026.1907445}
}
Kostenlos starten →